Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

Blood

Volumn 129, Issue 18, 2017, Pages 2570-2580

  Du, Jing ^a   Paz, Katelyn ^a   Flynn, Ryan ^a   Vulic, Ante ^b   Robinson, Tara M ^b   Lineburg, Katie E ^c   Alexander, Kylie A ^c   Meng, Jingjing ^d   Roy, Sabita ^d   Panoskaltsis Mortari, Angela ^a   Loschi, Michael ^a   Hill, Geoffrey R ^c   Serody, Jonathan S ^e   Maillard, Ivan ^f   Miklos, David ^g   Koreth, John ^h   Cutler, Corey S ^h   Antin, Joseph H ^h   Ritz, Jerome ^h   MacDonald, Kelli P ^c   Schacker, Timothy W ^a   Luznik, Leo ^b   Blazar, Bruce R ^a   more..

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA; CCL2 PROTEIN, MOUSE; IL17A PROTEIN, MOUSE; PYRIDONE DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BRONCHIOLITIS OBLITERANS; CELL INFILTRATION; CHEMOTAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; GERMINAL CENTER; IMMUNE RESPONSE; IN VITRO STUDY; LUNG FIBROSIS; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SKIN FIBROSIS; SPLEEN CELL; T LYMPHOCYTE; TFH CELL; ALLOGRAFT; ANIMAL; DISEASE MODEL; GENETICS; GRAFT VS HOST DISEASE; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MUTANT MOUSE STRAIN; PATHOLOGY; PULMONARY FIBROSIS; SKIN DISEASES;

ALLOGRAFTS; ANIMALS; B-LYMPHOCYTES; BRONCHIOLITIS OBLITERANS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTERLEUKIN-17; MACROPHAGES; MICE; MICE, MUTANT STRAINS; PULMONARY FIBROSIS; PYRIDONES; SKIN DISEASES; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFORMING GROWTH FACTOR BETA;

EID: 85019239756     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-01-758854     Document Type: Article

References (64)

1. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3): 374-384.
2. McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med. 2015;7(280): 280rv2-280rv2.
3. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16(12):1611-1628.
4. Chu Y-W, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14(4):365-378.
5. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011;4(3):318-333.
6. MacDonald KPA, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017; 129(1):13-21.
7. Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126.
8. Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23(2):211-234.
9. Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-1580.
10. Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123(25):3988-3998.
11. Alexander KA, Flynn R, Lineburg KE, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;13(8):1-15.
12. Radojcic V, Pletneva MA, Yen H-R, et al. STAT3 signaling in CD41 T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010;184(2):764-774.
13. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000; 24(5):477-491.
14. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291(1):367-373.
15. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999; 289(1):211-218.
16. Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med. 1997;216(3):392-397.
17. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005;201(6): 925-935.
18. Zhou C, Liu F, Gallo PH, Baratz ME, Kathju S, Satish L. Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts. BMC Musculoskelet Disord. 2016;17(1):469.
19. Zhou H, Latham CW, Zander DS, Margolin SB, Visner GA. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant. 2005;24(10):1577-1585.
20. Liu H, Drew P, Gaugler AC, Cheng Y, Visner GA. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant. 2005;5(6):1256-1263.
21. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1):L311-L318.
22. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem. 2000;204(1-2):119-126.
23. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1-3): 400-408.
24. Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol. 2008;8(5):679-687.
25. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
26. Rodríguez-Castellanos M, Tlacuilo-Parra A, Sánchez-Enríquez S, Vélez-Gómez E, Guevara-Gutiérrez E. Pirfenidone gel in patients with localized scleroderma: a phase II study. Arthritis Res Ther. 2015;16(6):510.
27. Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448-455.
28. Anderson BE, McNiff J, Yan J, et al. Memory CD41 T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112(1):101-108.
29. Bruedigam C, Bagger FO, Heidel FH, et al. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 2014; 15(6):775-790.
30. Estes JD, Reilly C, Trubey CM, et al. Antifibrotic therapy in simian immunodeficiency virus infection preserves CD41 T-cell populations and improves immune reconstitution with antiretroviral therapy. J Infect Dis. 2015;211(5):744-754.
31. Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med. 2007; 176(7):713-723.
32. Green TD, Park J, Yin Q, et al. Directed migration of mouse macrophages in vitro involves myristoylated alanine-rich C-kinase substrate (MARCKS) protein. J Leukoc Biol. 2012;92(3): 633-639.
33. Glaab T, Taube C, Braun A, Mitzner W. Invasive and noninvasive methods for studying pulmonary function in mice. Respir Res. 2007;8(1):63.
34. Dosanjh A, Ikonen T, Wan B, Morris RE. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther. 2002;15(5):433-437.
35. Akhurst RJ, Hata A. Targeting the TGFb signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790-811.
36. Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106(6):2206-2214.
37. Anderson KG, Sung H, Skon CN, et al. Cutting edge: intravascular staining redefines lung CD8 T cell responses. J Immunol. 2012;189(6): 2702-2706.
38. Anderson KG, Mayer-Barber K, Sung H, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc. 2014; 9(1):209-222.
39. Bedoret D, Wallemacq H, Marichal T, et al. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. J Clin Invest. 2009;119(12):3723-3738.
40. Doherty TA, Soroosh P, Khorram N, et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat Med. 2011;17(5):596-603.
41. Chen J-F, Ni H-F, Pan M-M, et al. Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol. 2013;304(6):F676-F685.
42. Erbel C, Akhavanpoor M, Okuyucu D, et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol. 2014;193(9):4344-4355.
43. Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17): 2144-2155.
44. Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood. 2004;103(6):2417-2426.
45. Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci. 2008;50(3):240-242.
46. Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol. 2010; 185(4):2502-2515.
47. Li W, Liu L, Gomez A, et al. Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight. 2016;1(6):1-17.
48. van der Waart AB, van der Velden WJFM, van Halteren AGS, et al. Decreased levels of circulating IL17-producing CD1611CCR61 T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation. PLoS One. 2012;7(12):e50896.
49. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant. 2012;18(1 Suppl): S56-S61.
50. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168(6): 3088-3098.
51. Kitko CL, White ES, Baird K. Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012; 18(1 Suppl):S46-S52.
52. Inomata M, Kamio K, Azuma A, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014;15(1):16.
53. Togami K, Kanehira Y, Tada H. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull. 2013;36(10): 1525-1527.
54. Giri SN, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos. 2002; 23(5):203-211.
55. Freshwater MF. Re: a controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients [letter]. Ann Plast Surg. 2012;69(1):111-112, author reply 111-112.
56. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol. 2005;27(4):247-249.
57. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005; 105(7):2973-2978.
58. Visner GA, Liu F, Bizargity P, et al. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation. 2009;88(3): 330-338.
59. Yasufuku K, Heidler KM, Woods KA, et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation. 2002;73(4):500-505.
60. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117(11):3498-3506.
61. Vittal R, Fan L, Greenspan DS, et al. IL-17 induces type V collagen overexpression and EMT via TGF-b-dependent pathways in obliterative bronchiolitis. Am J Physiol Lung Cell Mol Physiol. 2013;304(6):L401-L414.
62. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127(2):281-292.
63. Yoon H-K, Lim J-Y, Kim T-J, Cho C-S, Min C-K. Effects of pravastatin on murine chronic graft-versus-host disease. Transplantation. 2010;90(8): 853-860.
64. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001;108(4):547-556.